MARKET

MRNS

MRNS

Marinus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.29
-0.54
-4.56%
Closed 16:00 11/26 EST
OPEN
11.51
PREV CLOSE
11.83
HIGH
11.70
LOW
11.15
VOLUME
123.42K
TURNOVER
--
52 WEEK HIGH
20.04
52 WEEK LOW
10.71
MARKET CAP
415.09M
P/E (TTM)
-4.4052
1D
5D
1M
3M
1Y
5Y
Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that nine abstracts highlighting clinical trial and research data have...
Business Wire · 5d ago
Recap: Marinus Pharmaceuticals Q3 Earnings
  Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 11/09 13:11
BRIEF-Marinus Pharma Reports Third Quarter 2021 Financial Results
reuters.com · 11/09 12:14
Marinus Pharmaceuticals Q3 EPS $(0.53) Beats $(0.73) Estimate, Sales $10.11M Up From $171.00K YoY
Marinus Pharmaceuticals (NASDAQ:MRNS) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.73) by 27.4 percent. This is a 3.92 percent decrease over losses of $(0.51) per share
Benzinga · 11/09 12:10
Marinus Pharmaceuticals EPS beats by $0.12, beats on revenue
Marinus Pharmaceuticals (NASDAQ:MRNS): GAAP EPS of -$0.53 beats by $0.12. Revenue of $10.11M beats by $4.95M. Press Release
Seekingalpha · 11/09 12:09
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees. The Compensation...
Business Wire · 11/08 22:00
Marinus Pharmaceuticals Q3 2021 Earnings Preview
Marinus Pharmaceuticals (NASDAQ:MRNS) is scheduled to announce Q3 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is -$0.65 (-27.5% Y/Y) and the consensus Revenue Estimate
Seekingalpha · 11/08 17:28
Notable earnings before Tuesday's open
ADT,AGEN,AGTC,ALLT,APRN,AUD,OTCPK:BAYZF,BHVN,BNTX,BSY,CAH,CANO,CCO,CEVA,CNCE,CORR,DCTH,DHI,DRNA,EBIX,ECOM,EGRX,EPZM,EXK,FOLD,GILT,GLNG,GOL,HAE,HAIN,HGV,HUYA,IGT,IIVI,INSW,ISEE,ITCI,KNDI,KPLT,MIDD,MLCO,MNTV,MRNS,MRSN,MSGE,OTCPK:NSANY,NSPR,NUWE,OCGN,OESX,OSG...
Seekingalpha · 11/08 15:52
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRNS. Analyze the recent business situations of Marinus Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MRNS stock price target is 30.11 with a high estimate of 40.00 and a low estimate of 20.00.
High40.00
Average30.11
Low20.00
Current 11.29
EPS
Actual
Estimate
-0.61-0.46-0.30-0.15
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 143
Institutional Holdings: 44.04M
% Owned: 119.78%
Shares Outstanding: 36.77M
TypeInstitutionsShares
Increased
19
1.18M
New
11
952.80K
Decreased
23
696.79K
Sold Out
8
1.11M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
+0.44%
Key Executives
Non-Executive Chairman/Independent Director
Nicole Vitullo
President/Chief Executive Officer/Director
Scott Braunstein
Chief Financial Officer/Treasurer
Steven Pfanstiel
Vice President/General Counsel/Secretary
Martha Manning
Other
Joseph Hulihan
Director
Santiago Arroyo
Independent Director
Charles Austin
Independent Director
Michael Dougherty
Independent Director
Elan Ezickson
Independent Director
Seth Fischer
Independent Director
Timothy Mayleben
Independent Director
Saraswathy Nochur
No Data
About MRNS
Marinus Pharmaceuticals Inc is a United States-based biopharmaceutical company. The Company offers development and commercialization of medical drugs for the treatment of serious neurological and psychiatric disorders such as epilepsy, post-traumatic stress, and fragile-x syndrome. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Webull offers kinds of Marinus Pharmaceuticals Inc stock information, including NASDAQ:MRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRNS stock methods without spending real money on the virtual paper trading platform.